biostudies-literatureUnknown18(3)Liu YSC1011 (sufenidone) is a novel pyridone derivative with therapeutic potential for idiopathic pulmonary fibrosis (IPF). Two Phase 1 studies evaluated the safety and pharmacokinetics of single (SAD) and multiple ascending doses (MAD) of SC1011 immediate-release (IR) and modified-release (MR) oral formulations in healthy adult subjects. In Phase 1a, subjects were randomized to receive oral SC1011 IR or placebo in SAD (50 mg-300 mg) or MAD (100 mg and 200 mg) twice daily for 7 days. The Phase 1b study consisted of three treatment groups that received 100, 150, or 200 mg SC1011 MR twice daily for 7 days. SC1011 IR was absorbed rapidly (mean time to maximum concentration, T_max ≤ 1 h) and eliminated rapidly (mean terminal half-life, t_1/2: 1.23-2.64 h) following 50-300 mg sinClinical and translational sciencee70179https://www.ebi.ac.uk/biostudies/studies/S-EPMC11893723biostudies-literatureSafety, Tolerability, and Pharmacokinetics of SC1011 (Sufenidone), a Novel Antifibrotic Small Molecule, in Phase 1 Studies in Healthy Subjects.PMC11893723Qian HJiang FZan BZhu HDu YLiu SZeng YSun XTang HLiu YLi YYang ZGe ZChen XTang YfalseSafety, Tolerability, and Pharmacokinetics of SC1011 (Sufenidone), a Novel Antifibrotic Small Molecule, in Phase 1 Studies in Healthy Subjects.SC1011 (sufenidone) is a novel pyridone derivative with therapeutic potential for idiopathic pulmonary fibrosis (IPF). Two Phase 1 studies evaluated the safety and pharmacokinetics of single (SAD) and multiple ascending doses (MAD) of SC1011 immediate-release (IR) and modified-release (MR) oral formulations in healthy adult subjects. In Phase 1a, subjects were randomized to receive oral SC1011 IR or placebo in SAD (50 mg-300 mg) or MAD (100 mg and 200 mg) twice daily for 7 days. The Phase 1b study consisted of three treatment groups that received 100, 150, or 200 mg SC1011 MR twice daily for 7 days. SC1011 IR was absorbed rapidly (mean time to maximum concentration, T_max ≤ 1 h) and eliminated rapidly (mean terminal half-life, t_1/2: 1.23-2.64 h) following 50-300 mg sin2025-01-01T00:00:00Z2025 Mar2025-04-26T02:41:01.958Z2025-04-06T10:36:33.504ZS-EPMC118937234006555710.1111/cts.70179